A study presented at the ESMO Congress in 2024 found that combining standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma. The study, known as AIO-STO-0417 (MOONLIGHT), aimed to explore whether adding doublet immunotherapy to chemotherapy would provide additional benefits. Results showed that the addition of immunotherapy had no significant effect on progression-free survival or overall survival compared to chemotherapy alone. The study also found that the combination of triplet chemotherapy (FLOT) with nivolumab showed potential for improved efficacy. However, more research is needed due to low PD-L1 expression rates in all treatment arms.
Source link
Doublet Immunotherapy Disappoints in Gastric Cancer Study
